Discover and read the best of Twitter Threads about #WCLC2018
Most recents (1)
#ESMOAsia19 Dr. Ross Camidge with the updated results from the phase 3 ALTA-1L study of first-line brigatinib versus crizotinib in #ALK #NSCLC - at interim analysis presented at @IASLC #WCLC2018, study met its primary endpoint. Here are updates with longer f/u. #LCSM #LCAM 
@IASLC #ESMOAsia19 Primary endpoint of BIRC PFS showed HR 0.49 (95% CI, 0.35-0.68) with 2-year PFS rate 48% vs. 26% and investigator assessed PFS HR 0.43 #OncoAlert #LCSM
@IASLC #ESMOAsia19 Very impressive outcomes in patients with brain metastases at baseline (PFS HR 0.25)! Very good tolerability, early pulmonary events in this setting very uncommon. Good to have a new standard of care option for patients with #ALK #NSCLC - #LCSM #LCAM #OncoAlert
